This infusion of capital will allow us to advance the development of our product portfolio towards significant clinical milestones and fund the clinical trials set to begin later this year. Importantly, this transaction attracted investors who appreciate the promise and value of the merged company and its balanced portfolio of product candidates. We are delighted to welcome these new institutional stockholders. As a newly public company, we look forward to continuing to build our investor base and achieve our milestones.
- Jack Talley
HTML Medium Image Quote Embed:
HTML Large Image Quote Embed:
HTML Text Quote Embed with <blockquote>:
BB Forums Medium Image Quote Embed with <BB Code>:
Please login in order to submit reports.